Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SPRO

Spero Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SPRO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.14

Spero Therapeutics, Inc. (NASDAQ: SPRO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:13 UTC.

What Spero Therapeutics, Inc. does

Oxford Ledge operates as a clinical-stage biopharmaceutical company established to identify and develop novel treatments for rare diseases and conditions with significant unmet medical needs. The company has not generated revenue from product sales and focuses its efforts on acquiring product rights, building intellectual property, and conducting research and development. The company's lead candidate, tebipenem HBr, is designed as an oral carbapenem to treat complicated urinary tract infections in adults and has completed a Phase 3 trial that met its primary endpoint.

Summarized from Spero Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.14
Return on equity14.52%

Revenue, margins & earnings

FY2021: net loss $90M on revenue $18M$18MFY2021FY2022 Revenue: $54M — margin split not shown (non-operating gains)$54MFY2022FY2023 Revenue: $104M — margin split not shown (non-operating gains)$104MFY2023FY2024: net loss $69M on revenue $48M$48MFY2024FY2025 Revenue: $67M — margin split not shown (non-operating gains)$67MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-06
  • 2026-08-06Chief Medical OfficerAward162,311—
  • 2026-08-06Chief Medical OfficerStock option (right to buy)Award324,675—
  • 2026-06-25DirectorAward10,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Spero Therapeutics, Inc. do?

Oxford Ledge operates as a clinical-stage biopharmaceutical company established to identify and develop novel treatments for rare diseases and conditions with significant unmet medical needs.

When did SPRO last file with the SEC?

Spero Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:13 UTC. This page is also available as JSON at /api/data?ticker=SPRO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SPRO and 5,000+ tickers.

Create a free account — keep SPRO
For your agent
GET /api/data?ticker=SPRO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt